Business
Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes
Label expansion makes Omnipod 5 commercially available to 6 million people living with insulin-requiring type 2 diabetes Omnipod 5 is the first and only
About this update from Insulet Corporation
[{"type":"text","content":"\n\nLabel expansion makes Omnipod 5 commercially available to 6 million people living with insulin-requiring type 2 diabetes\n\n\n\nOmnipod 5 is the first and only automated insulin delivery (AID) system indicated for both type 1 and type 2 diabetes\n\n\n\n ACTON, Mass.--(BUSINESS WIRE)--\nInsulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its groundbreaking Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now indicated for use by people with type 2 diabetes (ages 18 years and older) in the U.S., making it the first and only AID system FDA-cleared for both type 1 and type 2 diabetes management.\n\n\n“Today’s announcement represents a significant milestone in providing easy-to-use, patient-centric technology for the treatment of type 2 diabetes,” said Jim Hollingshead, Insulet President and Chief Executive Officer. “Insulet is paving the way for these individuals to achieve better health outcomes while living with greater confidence and freedom through the game-changing benefits of tubeless Pod therapy. Omnipod 5 is setting a new standard in diabetes management, and we are thrilled with the opportunity to make a lasting impact on the insulin-requiring type 2 diabetes community.”\n\n\nThere are over 30 million people living with type 2 diabetes in the U.S.1, with approximately 6 million people who require insulin, of which 2.5 million are using multiple daily injections (MDI)2. Despite advances in medical therapy over the past 20 years, there has been no significant change in the percentage of adults with type 2 diabetes achieving recommended HbA1c targets3. Only a quarter of individuals with type 2 diabetes on insulin are achieving an HbA1c of 7.0% or less, and half of this population has an HbA1c greater than 8.0%4. Despite guideline recommendations for insulin treatment in advanced disease, insulin therapy is often delayed or not appropriately intensified5.\n\n\nInsulet recently presented data showing that Omnipod 5 significantly improves health outcomes while making life easier for people with type 2 diabetes. The SECURE-T2D clinical study demonstrated that compared to prior insulin therapy methods in adults with type 2 diabetes, Omnipod 5 use resulted in considerable reductions in HbA1c: 0.8% overall ...